All Updates

All Updates

icon
Filter
Partnerships
Absci partners with Almirall to develop AI-designed dermatological treatments
AI Drug Discovery
Nov 14, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Nov 14, 2023

Absci partners with Almirall to develop AI-designed dermatological treatments

Partnerships

  • Washington-based AI-powered synthetic biology company AbSci and Spain-based AI drug discovery company Almirall have collaborated to develop and commercialize AI-designed dermatological therapies. Absci will receive up to USD 650 million in upfront fees, R&D, and post-approval milestone payments of the two programs under the terms of the agreement.

  • The partnership will combine Absci's AI technology and Almirall’s expertise in dermatology to generate medicines for patients. Absci will create and commercialize potential drug candidates for two dermatological targets leveraging its de novo GenAI platform. This strategic agreement is Almirall's first venture into AI therapeutic collaborations and comes after Absci's announcement of its AI's capability to design, validate, and produce therapeutic antibodies. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.